pembrolizumab,enfortumab vedotin
merck,astellas,seagen
['ev-302', 'ev-103', ' ev ', 'pembro']
ev-103 (cohort k): ev +/- pembro in cis-inelig untreated muc. high activity, hopefully ev-302 trial will show us the role of this combo in this setting. #esmo22 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid